SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Gillsoft Solution
Gillsoft Solution Spółka z Ograniczoną Odpowiedzialnością
Gillsoft Solution Spółka z Ograniczoną Odpowiedzialnością (KRS 0000692002, NIP 6751608343) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. GILLSOFT SOLUTION operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since August 30, 2017.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Founded
August 30, 2017
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
N/A
Registry entries
6
latest: November 5, 2018
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Gillsoft Solution.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Competing companies or those operating in the same market segment as Gillsoft Solution (in Kraków, industry: Research and development).
KRAKÓW· Research and development
Revenue 2024: 105.6 M PLN
KRAKÓW· Research and development
Revenue 2024: 75.7 M PLN
KRAKÓW· Research and development
Revenue 2024: 53.6 M PLN
TOMASZOWICE· Research and development
Revenue 2021: 26.4 M PLN
KRAKÓW· Research and development
Revenue 2025: 22.1 M PLN
M. KRAKÓW· Research and development
Revenue 2023: 20.4 M PLN
Latest reporting year
2017
Available years
1
Filing entries
0
6 historical registry entries for Gillsoft Solution
Identifier change
KR.XI NS-REJ.KRS/25224/17/839/REGON
Identifier change
KR.XI NS-REJ.KRS/25224/17/839/NIP
Board change
KR.XI NS-REJ.KRS/35104/17/103
Financial statement filed, Approval of the financial statement, Change in Section 3 (business activity and filings)
KR.XI NS-REJ.KRS/29035/18/646
Company name change, Board change, Shareholder change, Articles of association amended, Primary PKD code change, Secondary PKD code change
KR.XI NS-REJ.KRS/31986/18/0
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Gillsoft Solution Spółka z Ograniczoną Odpowiedzialnością
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
GILLSOFT SOLUTION's board has 2 members.